Ansun Biopharma closes $80M Series B; RedHill Biopharma ties up with Cosmo Pharmaceuticals
→ San Diego-based Ansun Biopharma recently closed an $80 million Series B funding round, led by China Investors, according to ChinaBio Today. The funds will be used to help advance the company’s lead antiviral, which already been granted fast track eligibility and breakthrough therapy status by the FDA in the US and is being reviewed for the treatment of lower respiratory tract infections caused by parainfluenza virus (PIV) in immunodeficient patients.
→ While waiting for the decision on their drug Talicia for the treatment of H. pylori infection by the FDA — RedHill Biopharma is entering into a strategic collaboration with Cosmo Pharmaceuticals. Under the agreement, Cosmo is granting RedHill the exclusive license agreement for the US rights to Aemcolo — an antibiotic for the treatment of travelers’ diarrhea caused by non-invasive strains of E. coli in adults — in addition to a private investment totaling $36.3 million.